Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
NCT04412096Phase 4Completed
- Sponsor
- The Ohio State University
- Start
- Nov 2020
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of timolol, latanoprost ophthalmic solution 0.005% (TearClear TC-002) in Glaucoma, ocular hypertension, sponsored by The Ohio State University. Started Nov 2020; status: completed.
02
Drugs
timolollatanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT04412096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04412096.